Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TECH logo TECH
Upturn stock ratingUpturn stock rating
TECH logo

Bio-Techne Corp (TECH)

Upturn stock ratingUpturn stock rating
$53.74
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TECH (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

15 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $64.15

1 Year Target Price $64.15

Analysts Price Target For last 52 week
$64.15 Target price
52w Low $45.94
Current$53.74
52w High $80.64

Analysis of Past Performance

Type Stock
Historic Profit -46.04%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 8.42B USD
Price to earnings Ratio 116.83
1Y Target Price 64.15
Price to earnings Ratio 116.83
1Y Target Price 64.15
Volume (30-day avg) 15
Beta 1.39
52 Weeks Range 45.94 - 80.64
Updated Date 08/15/2025
52 Weeks Range 45.94 - 80.64
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.46

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-06
When -
Estimate 0.5
Actual 0.53

Profitability

Profit Margin 6.02%
Operating Margin (TTM) -3.64%

Management Effectiveness

Return on Assets (TTM) 2.92%
Return on Equity (TTM) 3.68%

Valuation

Trailing PE 116.83
Forward PE 26.53
Enterprise Value 8858610709
Price to Sales(TTM) 6.91
Enterprise Value 8858610709
Price to Sales(TTM) 6.91
Enterprise Value to Revenue 7.26
Enterprise Value to EBITDA 41.75
Shares Outstanding 156767008
Shares Floating 153078830
Shares Outstanding 156767008
Shares Floating 153078830
Percent Insiders 1.08
Percent Institutions 101.68

ai summary icon Upturn AI SWOT

Bio-Techne Corp

stock logo

Company Overview

overview logo History and Background

Bio-Techne Corp. was founded in 1981. Initially focused on producing recombinant proteins, the company expanded through acquisitions and organic growth to offer a broader range of products and services for the life science industry.

business area logo Core Business Areas

  • Protein Sciences: Develops and manufactures recombinant and native proteins, antibodies, immunoassays, and related reagents.
  • Diagnostics and Genomics: Offers molecular controls, reagents, instruments, and targeted DNA/RNA sequencing solutions for diagnostics.
  • Cell and Gene Therapy: Provides tools and technologies for cell culture, cell activation, gene editing, and cell therapy manufacturing.

leadership logo Leadership and Structure

Charles Kummeth is the President and CEO. The company has a functional organizational structure with divisions based on product lines and services, overseen by a board of directors.

Top Products and Market Share

overview logo Key Offerings

  • Proteins & Reagents: A wide range of recombinant proteins, antibodies, and chemical products essential for research. Competitors include Thermo Fisher Scientific and Merck. Market share and revenue per product are not publicly disclosed with enough granularity to be accurate; however, this segment contributes substantially to overall revenue.
  • Exosome Diagnostics: Develops liquid biopsy tests for cancer diagnosis and monitoring. Competitors include Qiagen and Roche. Market share data is not publicly available, but this area has high growth potential.
  • Advanced Cell Diagnostics (ACD): RNAscopeu00ae and BaseScopeu2122 platforms for in situ hybridization assays. Competitors include Qiagen and Danaher's Leica Biosystems. Market share is not specifically disclosed, but it's a key driver of growth.

Market Dynamics

industry overview logo Industry Overview

The life science tools and diagnostics industry is experiencing growth driven by increasing research funding, advancements in genomics and proteomics, and the development of personalized medicine. The industry is characterized by intense competition and technological innovation.

Positioning

Bio-Techne Corp. holds a strong position in the protein sciences and cell and gene therapy markets, with a reputation for high-quality products and innovative technologies. Their competitive advantage lies in their diverse product portfolio and strong brand recognition.

Total Addressable Market (TAM)

The global life science tools market is estimated to be over $100 billion. Bio-Techne is positioned to capture a significant portion of this TAM through its diversified product offerings and strategic acquisitions.

Upturn SWOT Analysis

Strengths

  • Diversified product portfolio
  • Strong brand reputation
  • Focus on high-growth markets (cell and gene therapy)
  • Established customer base
  • Strategic acquisitions

Weaknesses

  • High reliance on research funding
  • Integration risks associated with acquisitions
  • Competition from larger players
  • Relatively smaller size compared to some competitors

Opportunities

  • Expanding into emerging markets
  • Developing new diagnostic and therapeutic tools
  • Capitalizing on the growth of personalized medicine
  • Leveraging data analytics to improve product development
  • Growth in Cell and Gene Therapy Market

Threats

  • Economic downturns affecting research funding
  • Intense competition
  • Regulatory changes impacting diagnostic products
  • Technological obsolescence
  • Supply chain disruptions

Competitors and Market Share

competitor logo Key Competitors

  • TMO
  • DHR
  • ILMN
  • WAT

Competitive Landscape

Bio-Techne faces competition from larger, more diversified companies with greater resources. However, Bio-Techne's focus on specific niches and its reputation for quality give it a competitive advantage. The competitive landscape includes companies specializing in life science tools, diagnostics, and biopharmaceuticals.

Major Acquisitions

Asuragen

  • Year: 2019
  • Acquisition Price (USD millions): 320
  • Strategic Rationale: Expanded Bio-Techne's molecular diagnostics portfolio and capabilities.

Growth Trajectory and Initiatives

Historical Growth: Bio-Techne has demonstrated consistent growth over the past decade, driven by organic growth and strategic acquisitions. The company's focus on high-growth markets, such as cell and gene therapy, has contributed to its success.

Future Projections: Analysts predict continued growth for Bio-Techne, driven by increasing demand for life science tools and diagnostics. Growth rate forecasts vary depending on market conditions and company performance.

Recent Initiatives: Recent initiatives include acquisitions of companies specializing in cell and gene therapy, expansion of product offerings, and investments in R&D.

Summary

Bio-Techne is a well-positioned player in the life science tools and diagnostics market, particularly with its focus on high-growth areas like cell and gene therapy. Strategic acquisitions and a strong product portfolio have fueled growth, but competition from larger players remains a significant challenge. The company's success hinges on continued innovation and effective integration of acquired businesses. Monitoring economic trends and adapting to regulatory changes are also crucial.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Market Research Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on available estimates and may not be precise. Financial data should be verified with official sources.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bio-Techne Corp

Exchange NASDAQ
Headquaters Minneapolis, MN, United States
IPO Launch date 1989-02-09
CEO, President & Director Mr. Kim Kelderman
Sector Healthcare
Industry Biotechnology
Full time employees 3100
Full time employees 3100

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.